Skip to main content
Category

Treatments

Targeted Oncology
ResearchTreatments

Frontline Combinations Better Survival Rates in EGFRm Lung Cancer

*November 2023* First-line combination treatment regimens are improving progression-free survival (PFS) rates in patients with EGFR-mutated non–small cell lung cancer (NSCLC), according to Julia Rotow, MD.1 Prior to November 2023, the main first-line therapy utilized for the treatment of patients with EGFR-mutated lung cancer was osimertinib (Tagrisso) monotherapy, based on the phase…
laurabbook@gmail.com
December 27, 2023
OncLive
ResearchTreatments

Dato-DXd Significantly Improves PFS in Select Subsets of Advanced/Metastatic NSCLC

*October 2023* Take home message: Comparison Dato-DXd, a novel TROP2-directed antibody-drug conjugate, to docetaxel in pretreated advanced/metastatic non-small cell lung cancer (NSCLC) patients, revealing significantly improved progression-free survival with Dato-DXd, especially in non-squamous histology patients, while demonstrating a manageable safety profile and ongoing evaluation of overall survival. (From OncoAlert) The Trop-2…
laurabbook@gmail.com
December 27, 2023
journal of clinical oncology logo
ResearchTreatments

A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)

*October 2023* PURPOSE In the treatment of non-small cell lung cancer (NSCLC) with a driver mutation, the role of anti-PD-(L)1 antibody following tyrosine kinase inhibitor (TKI) remains unclear. This randomized, open-label, multicenter, phase 3 study evaluates the efficacy of atezolizumab plus bevacizumab, paclitaxel and carboplatin (ABCP) in EGFR or ALK-mutated NSCLC that progressed…
laurabbook@gmail.com
December 24, 2023
OncLive
ResearchTreatments

Trastuzumab Deruxtecan Wins EU Approval for HER2-Mutated Advanced NSCLC (DESTINY-Lung02 trial)

*October 2023* The European Commission (EC) has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor an activating HER2 mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.1 The regulatory decision was supported by data from the phase…
laurabbook@gmail.com
December 24, 2023
Targeted Oncology
ResearchTreatments

EGFR Exon 20-Insertion NSCLC Population Sees PFS Benefit from Amivantamab/Chemotherapy (PAPILLON Trial)

*October 2023* Take home message: Amivantamab in combination with chemotherapy showed significantly improved PFS and a higher response rate compared to chemotherapy alone in treatment-naive patients with advanced non-small-cell lung cancer harboring EGFR exon 20 insertions, demonstrating its efficacy as a first-line treatment. The phase 3 PAPILLON trial (NCT04538664) resulted in…
laurabbook@gmail.com
December 24, 2023
Onc Live
ResearchTreatments

Osimertinib Plus Chemo Improves CNS PFS in EGFR+ Advanced NSCLC With Baseline Brain Metastases

*October 2023* Osimertinib (Tagrisso) plus chemotherapy reduced the risk of central nervous system (CNS) disease progression or death vs osimertinib alone in patients with locally advanced or metastatic EGFR-positive non–small cell lung cancer (NSCLC) who had brain metastases at baseline, according to data from the phase 3 FLAURA2 trial (NCT04035486) presented…
laurabbook@gmail.com
December 24, 2023